Questcor continues plunge; FDA reviewing Citron-backed lab tests

|By:, SA News Editor

The FDA tells Bloomberg it's reviewing the lab tests of Questcor's (QCOR -8.8%) Acthar gel discussed by Citron Research in a 24-page report published yesterday. Citron claimed the tests showed almost no detectable amounts of the hormone ACTH, which Questcor has said it believes is the primary active ingredient within Acthar.

Shares are now down 17% from Wednesday's close.